ABIVAX Société Anonyme (EPA:ABVX)
104.10
-1.40 (-1.33%)
May 11, 2026, 5:35 PM CET
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 69 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
69
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€66,232
Profits / Employee
€4,871,043
Market Cap
8.35B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | 0 | - | 69 | 0 |
| Dec 31, 2024 | 69 | 8 | 13.11% | 69 | 0 |
| Dec 31, 2023 | 61 | 37 | 154.17% | 61 | 0 |
| Dec 31, 2022 | 24 | 0 | - | 24 | 0 |
| Dec 31, 2021 | 24 | -3 | -11.11% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Cellectis | 229 |
| Genfit | 188 |
| MedinCell | 145 |
| Transgene | 145 |
| DBV Technologies | 117 |
| Nanobiotix | 100 |
| Inventiva | 77 |
ABIVAX Société Anonyme News
- 6 days ago - Abivax Repurchases Royalty Certificates And Prices $45M ADS Offering To Strengthen Balance Sheet - Nasdaq
- 6 days ago - Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares - GlobeNewsWire
- 13 days ago - Abivax call volume above normal and directionally bullish - TheFly
- 18 days ago - Abivax to Present Data on Obefazimod at Digestive Disease Week® - GlobeNewsWire
- 20 days ago - Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents - GlobeNewsWire
- 4 weeks ago - Abivax price target raised to EUR 120 from EUR 88 at Oddo BHF - TheFly
- 4 weeks ago - This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy? - The Motley Fool
- 5 weeks ago - Abivax appoints Michael Nesrallah as chief commercial officer - TheFly